Similar articles for PMID: 27340608

Year	Number of Results
2000	1
2001	1
2004	4
2005	3
2006	1
2007	2
2009	2
2010	6
2011	4
2012	13
2013	11
2014	8
2015	15
2016	20
2017	15
2018	14
2019	21
2020	9
2021	19
2022	10
2023	7
2024	0

1

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K. Pham T, et al. Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015. Exp Hematol Oncol. 2016. PMID: 27340608 Free PMC article. Review.

2

Targeting the androgen receptor signaling pathway in advanced prostate cancer.

Chung C, Abboud K. Chung C, et al. Am J Health Syst Pharm. 2022 Jul 22;79(15):1224-1235. doi: 10.1093/ajhp/zxac105. Am J Health Syst Pharm. 2022. PMID: 35390118 Review.

3

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL. Shafi AA, et al. Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.

4

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348

5

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N. Sharifi N. Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. doi: 10.2174/187152009789735044. Anticancer Agents Med Chem. 2009. PMID: 19719456 Review.

6

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.

Li JR, Chiu KY, Wang SS, Yang CK, Chen CS, Ho HC, Hung CF, Cheng CL, Yang CR, Chen CC, Wang SC, Lin CY, Chang CH, Hsu CY, Ou YC. Li JR, et al. Front Pharmacol. 2017 Nov 22;8:836. doi: 10.3389/fphar.2017.00836. eCollection 2017. Front Pharmacol. 2017. PMID: 29213237 Free PMC article.

7

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

Merseburger AS, Hupe MC. Merseburger AS, et al. Adv Ther. 2016 Jul;33(7):1072-93. doi: 10.1007/s12325-016-0351-4. Epub 2016 May 31. Adv Ther. 2016. PMID: 27246172 Free PMC article. Review.

8

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Fizazi K, Smith MR, Tombal B. Fizazi K, et al. Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. Clin Genitourin Cancer. 2018. PMID: 30197098 Free article. Review.

9

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. Mottet N, et al. Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Actas Urol Esp. 2011. PMID: 21757258 Spanish.

10

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP. Chandrasekar T, et al. Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Transl Androl Urol. 2015. PMID: 26814148 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

170 results

Results by year